Das neue langwirksame GLP-1-Analogon Dulaglutide wird im AWARD-Studienprogramm entweder mit Exenatide 2x täglich und Plazebo, mit Metformin oder mit Sitagliptin verglichen. Ergebnisse nach bis zu ...

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Dulaglutide is a novel long-acting GLP-1 receptor agonist, which has the function of glucose-dependent promotion of insulin secretion, and can reduce the risk of hypoglycemia compared with insulin ...

Dulaglutide is primarily used as a medication for adults with type 2 diabetes mellitus. It is prescribed as an adjunct to diet and exercise in order to improve glycemic control.

In conclusion, dulaglutide combined with insulin degludec can significantly reduce overall glucose fluctuations and appetite early in diabetes patients, resulting in a higher TIR. Therefore, when ...